Evidence map›Paper›PMID 40551505›Full record

ReviewBritish journal of haematology2025

Primary myelofibrosis with increased haemoglobin concentration at presentation.

Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Annalisa De Silvestri, Robert Peter Gale, Vittorio Rosti

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giovanni BarosiCenter for the Study of Myelofibrosis, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.ORCID https://orcid.org/0000-0002-8357-7192
Rita CampanelliCenter for the Study of Myelofibrosis, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
Paolo CatarsiCenter for the Study of Myelofibrosis, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
Carlotta AbbàGeneral Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
Adriana CaroleiCenter for the Study of Myelofibrosis, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
Margherita MassaGeneral Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.ORCID https://orcid.org/0000-0001-8037-0439
Annalisa De SilvestriBiometry and Clinical Epidemiology, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
Robert Peter GaleCentre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-9156-1676
Vittorio RostiCenter for the Study of Myelofibrosis, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.ORCID https://orcid.org/0000-0003-4195-2289

Funding

AIRC 5 x 1000 MYNERVA project 21267UK National Institute of Health Research (NIHR)
6 · The paper itself

Abstract

One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia-CSM database had haemoglobin concentration at diagnosis ≥160 g/L in females or ≥ 165 g/L in males. These subjects were more often female and younger; had higher white blood cell (WBC) and platelet concentrations; and higher frequency of JAK2

Indexed as

HemoglobinsPrimary MyelofibrosisAdultAgedAged, 80 and overFemaleHumansJanus Kinase 2MaleMiddle AgedPrognosisHemoglobinsJAK2 protein, humanJanus Kinase 2haematological malignancymyelofibrosismyeloproliferative disorderpolycythaemia vera

Identifiers

PMID40551505
PMCPMC12624203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.